Foxy-5

Foxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, and Metastatic Prostate Cancer.

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.
Foxy-5(CAS 881188-51-8)

CAT No: R1861

CAS No:881188-51-8

Synonyms/Alias:FOXY-5;881188-51-8;FOXY5;Foxy 5;N-Formyl-Met-Asp-Gly-Cys-Glu-Leu;WNT-5A derived hexapeptide FOXY-5;CBZ9UL0ARB;UNII-CBZ9UL0ARB;L-Leucine,N-formyl-L-methionyl-L-a-aspartylglycyl-L-cysteinyl-L-a-glutamyl-;L-Leucine, N-formyl-L-methionyl-L-alpha-aspartylglycyl-L-cysteinyl-L-alpha-glutamyl-;(2S)-2-[[(2S)-4-carboxy-2-[[(2R)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]propanoyl]amino]acetyl]amino]-3-sulfanylpropanoyl]amino]butanoyl]amino]-4-methylpentanoic acid;(2S,5S,8R,14S)-5-(2-carboxyethyl)-14-((S)-2-formamido-4-(methylthio)butanamido)-2-isobutyl-8-(mercaptomethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazahexadecanedioic acid;L-LEUCINE, N-FORMYL-L-METHIONYL-L-.ALPHA.-ASPARTYLGLYCYL-L-CYSTEINYL-L-.ALPHA.-GLUTAMYL-;Wnt5a hexapeptide;(2S)-2-((2S)-4-carboxy-2-((2R)-2-(2-((2S)-3-carboxy-2-((2S)-2-formamido-4-(methylsulfanyl)butanamido)propanamido)acetamido)-3-sulfanylpropanamido)butanamido)-4-methylpentanoic acid;(2S)-2-[(2S)-4-carboxy-2-[(2R)-2-{2-[(2S)-3-carboxy-2-[(2S)-2-formamido-4-(methylsulfanyl)butanamido]propanamido]acetamido}-3-sulfanylpropanamido]butanamido]-4-methylpentanoic acid;Foxy 5 TFA;FOXY 5 [WHO-DD];FOXY-5 [WHO-DD];Foxy-5(Wnt5a peptide mimetic);CHEMBL4297281;SCHEMBL23477401;formyl-Met-Asp-Gly-Cys-Glu-Leu;Foxy-5(Wnt5a peptide mimetic)?;CHEBI:125492;Wnt-5a Mimic Hexapeptide Foxy-5;EX-A4066;HY-P1416;AKOS025147366;CCG-208076;DB13034;DA-73540;CS-0033287;NS00072887;BRD-K13005598-001-01-5;BRD-K13005598-001-02-3;Q27216112;

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
M.F/Formula
C26H42N6O12S2
M.W/Mr.
694.8
Sequence
One Letter Code:MDGCEL
Three Letter Code:For-Met-Asp-Gly-Cys-Glu-Leu-OH
Purity
> 95%
Activity
Wnt5a peptide mimetic. Impairs migration and invasion of 4T1 breast cancer cells in vitro. Also inhibits metastasis of inoculated 4T1 cells in mice.
Source#
Synthetic
Long-term Storage Conditions
Soluble to 1 mg/ml in PBS (pH 7.4); 10 mM in DMSO
Shipping Condition
Wet ice in continental US; may vary elsewhere
InChI
InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1
InChI Key
WFZPJYYCTSHDJI-ATIWLJMLSA-N

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
Peptide Modification ServicesPeptide Analysis ServicesPeptide Synthesis ServicesPeptide CDMOcGMP Peptide ServicePeptide Nucleic Acids SynthesisCustom Conjugation ServiceEpitope Mapping Services
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers